Lung cancer review reports better survival with tislelizumab regimens
Pooled trials favored tislelizumab regimens on survival, while higher rates of liver enzyme elevations complicated the safety picture.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Across randomized trials in lung cancer, tislelizumab given alone or alongside chemotherapy improved survival measures compared with chemotherapy alone. Overall adverse events did not differ significantly, but elevations in liver enzymes were more common. The abstract supports discussing these regimens' benefits and harms while leaving the absolute survival gain and follow-up duration unclear.
The abstract does not specify follow-up durations, absolute survival differences or detailed patient subgroups. Its pooled results cannot establish the expected benefit or safety profile for an individual patient.
What researchers found
Overall survival
Tislelizumab regimens had a lower estimated death rate at a given time: 0.69 times that with chemotherapy alone among patients still alive. Follow-up duration was not reported.
Reading the survival result
A hazard ratio compares the rate of death at a given time among people still alive. It does not tell us the absolute chance of death or how many extra months participants lived.
Safety needs separate attention
The overall adverse-event comparison was statistically nonsignificant, which does not prove equal safety. Elevated ALT and AST were more frequent with tislelizumab regimens; these are liver enzyme measurements, not a reported diagnosis of liver failure.
The original publication
Comparative safety and efficacy of tislelizumab-based regimens versus chemotherapy in lung cancer: a systematic review and meta-analysis.
Ullah A, Haider F, Ahmed F et al.
Front Oncol · 2025
- PubMed ID
- 41127016
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.